NeuroSense Therapeutics, Ltd. announces the presentation of the results of the phase IIa study at four international conferences

CAMBRIDGE, Mass., January 4, 2022 / PRNewswire / – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced that the presentation of the results of the Company’s Phase IIa clinical trial has been accepted at 16e International Conference on Alzheimer’s Disease and Parkinson’s Disease (AD / PD) to be held in Barcelona in March 2022. AD / PD is an international medical and scientific conference on Alzheimer’s and Parkinson’s disease and other neurological diseases.

(PRNewsfoto / NeuroSense Therapeutics)

During the fourth quarter of 2021, NeuroSense presented clinical and preclinical data at three prestigious conferences: the Annual ALS ONE Research Symposium; the 2021 ALS / MND Symposium; and the annual meeting of the Israeli Neurological Association.

The presentations also focused on the main clinical results of NeuroSense’s Phase IIa clinical study which showed promising clinical results as well as significant changes in biomarkers related to ALS.

“We are delighted and honored to present our work at these premier conferences, and we thank the organizers for giving us the opportunity to stand on the podium. Our results provided valuable information on the pathologies of ALS and the mechanism of action of PrimeC. , the flagship of our pipeline, ”noted Dr Shiran Zimri, PhD., Scientific Programs Manager at NeuroSense. “We hope that participation in these premier conferences will pave the way for further collaborations and the advancement of our product portfolio.”

Alon ben-noon, NeuroSense CEO added, “The positive reception NeuroSense has received from the scientific community helps underscore the novelty and importance of our PrimeC clinical trial results for ALS. With the recent completion of our IPO and NASDAQ listing, we are well funded to work closely with leading clinicians and patient advocacy groups and to advance our ALS clinical program towards the launch of our study. phase IIb. “

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on the discovery and development of treatments for patients with debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer’s disease, and Parkinson’s disease, among others, represent one of the greatest unmet medical needs of our time, with limited effective treatment options available for them. patients. Due to the complexity of neurodegenerative diseases, NeuroSense’s strategy is to develop combination therapies targeting several pathways associated with these diseases.

Forward-looking statements

This press release contains “forward-looking statements” which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate”, “believe”, “contemplate”, “might”, “estimate”, “expect”, “have the intention “,” seek, “” may “,” could “,” plan “,” potential “,” predict “,” plan “,” target “,” aim “,” should “,” will “,” would ” , or the negative of such words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to uncertainties, risks and assumptions. inherent that are difficult to predict and include statements about attending conferences; of society PrimeC development program; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials; the nature, strategy and direction of the business and subsequent updates thereon; and the development and commercial potential of any of the Company’s product candidates. In addition, certain forward-looking statements are based on assumptions about future events which may not prove to be correct. The forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. assumes no obligation to update this information, except as required by applicable law.

Cision

Cision

View original content to download multimedia: https://www.prnewswire.com/news-releases/neurosense-therapeutics-ltd-announces-the-presentation-of-phase-iia-study-results-at-four-international -conferences -301453632.html

SOURCE NeuroSense

About Stephen Arrington

Check Also

76ers vs. Heat score, takeaway: Miami advances to Conference Finals; James Harden and Joel Embiid fail

The Miami Heat are heading to the Eastern Conference Finals for the second time in …